Navigation Links
Abbott Researchers Focus on New Cutting-Edge Approaches in the,Fight Against Cancer

the Bcl-2 family of proteins interact with one another, leading researchers to develop a novel compound that causes cancer cells to self-destruct.

ABT-263 recently entered Phase I clinical trials for lymphomas and solid tumors, including small cell lung cancer. Preclinical data has shown that Abbott's Bcl-2 family protein inhibitors bind to Bcl-2 proteins, restoring cell death to cancerous cells. Additionally, the compounds were found to enhance the effects of chemotherapy and radiation used to treat other types of cancer, such as non-small cell lung cancer.

PARP Inhibitors (ABT-888)

DNA damaging agents remain some of the most successful treatments for cancer. The enzyme Poly(ADP-ribose)polymerase (abbreviated PARP) can help repair DNA damage caused by these agents used to treat cancer and render them ineffective. As PARP activity is often increased in cancer cells, it provides these cells with a survival mechanism.

ABT-888 is an oral PARP-inhibitor developed by Abbott researchers to prevent DNA repair in cancer cells and increase the effectiveness of common cancer therapies such as radiation and alkylating agents.

ABT-888 has entered a Phase 0 trial for patients with refractory solid tumors and lymphoid malignancies, and will enter Phase I trials for melanoma this year. Preclinical data indicates ABT-888 has improved the effectiveness of radiation and many types of chemotherapy in animal models of cancer.

Kinase Inhibitors (ABT-869)

Many oncology researchers are currently developing agents that target kinases, a class of enzymes that are often overly activated in cancer cells. Inhibition of the appropriate kinases can suppress tumor growth by cutting off its blood supply.

Discovered by Abbott scientists, ABT-869 is a multitargeted kinase inhibitor that is in Phase I clinical trials for solid tumors and selected hematologic malignancies such as leukemia. Phase II trials for several tumor types will also begin t
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
2. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
4. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
5. Abbotts Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
6. Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and Effective Treatment to Reduce Risk of Stroke
7. Abbott Announces Positive Six-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
8. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
9. Abbott to Present New Data Across its Vascular Portfolio at the American College of Cardiologys 56th Annual Scientific Session
10. NIEHS Researchers Identify Enzyme Critical in DNA Replication
11. Stanford Researchers Find Brain Pathway of Depression in Rats
Post Your Comments:
(Date:3/2/2015)... SINGAPORE , March 2, 2015 Mount ... center in Singapore to treat ... radiosurgery from Varian Medical Systems (NYSE: VAR ... introduced the new system, which enables advanced forms of ... shaped high-energy radiation beams to attack a tumor from ...
(Date:3/2/2015)... 2015 Valencia Technologies Corporation (" Valencia ... its radically small device for the treatment of high ... this randomized, double-blinded, controlled trial are compelling and provide ... it will succeed in a large U.S. trial for ... Valencia has successfully raised more ...
(Date:3/2/2015)... , March 2, 2015  CytomX, a ... of cancer, today announced the creation of scientific ... and clinicians in the fields of cancer immunotherapy ... new advisory boards will provide guidance to CytomX ... of precision immunotherapies and Probody drug conjugates. The ...
Breaking Medicine Technology:Mount Elizabeth Novena Hospital to Deliver First TrueBeam STx Radiosurgery Treatments in Singapore 2Mount Elizabeth Novena Hospital to Deliver First TrueBeam STx Radiosurgery Treatments in Singapore 3Valencia Technologies Implants its 48th Patient, Continues Equity Crowdfunding 2CytomX Expands Scientific and Clinical Advisory Boards with Leading Experts in Cancer Immunotherapy and Antibody Drug Conjugates 2CytomX Expands Scientific and Clinical Advisory Boards with Leading Experts in Cancer Immunotherapy and Antibody Drug Conjugates 3
... Following recent FDA approvals for prostate cancer treatment ... that the lives of men with advanced prostate cancer ... medication from Johnson & Johnson. The drug, which could reach ... news with the potential to change clinical practice by ...
... SPRING, Md., Oct. 13 The Food and Drug Administration ... a rare type of thigh bone fracture in people ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) (Logo: ... warning because the rare type of fracture has been ...
Cached Medicine Technology:Robotic Prostatectomy Expert Dr. David Samadi, MD Discusses Prostate Cancer Treatment Drug Abiraterone 2
(Date:3/2/2015)... March 02, 2015 Robins & Morton ... conjunction with Women in Construction Week (March 1-7, sponsored ... NAWIC) and National Women’s History Month, Robins & Morton ... affect the company and the construction industry as a ... to the dozens of roles in between, each woman ...
(Date:3/2/2015)... The Workgroup for Electronic Data Interchange (WEDI), ... health IT to create efficiencies in healthcare information exchange, ... Providers.” The white paper by WEDI’s ICD-10 Testing Subworkgroup ... testing by focusing on primary considerations and steps for ... October 1, 2015 implementation date. Download the white ...
(Date:3/2/2015)... This year, the National Multiple Sclerosis Society’s annual ... for people across the country to unite, raise awareness, ... live their best lives. MS Awareness Week is a special ... join the Society’s vision of a world free of MS. ... of the central nervous system, interrupts the flow of information ...
(Date:3/2/2015)... March 02, 2015 Four Seasons Resort Maui ... its 25th anniversary this year, having officially opened its doors ... luxury resort is honoring over 70 employees who started on ... from amongst the approximately 400 original employees. The celebration ... Oceanfront Lawn. , This Four Seasons flagship resort, ...
(Date:3/2/2015)... March 02, 2015 What are the ... physicians request references? When are interviews scheduled, how can ... opportunities?, Both training and practicing physicians who are looking ... questions and more at the PracticeLink Physician Career Advancement ... drop-in Job Fair is from 5:30 to 8:30 p.m. ...
Breaking Medicine News(10 mins):Health News:Robins & Morton Recognizes Women In Construction 2Health News:WEDI Releases New White Paper on ICD-10 Testing for Small Providers 2Health News:Every Connection Counts During MS Awareness Week 2Health News:Every Connection Counts During MS Awareness Week 3Health News:Every Connection Counts During MS Awareness Week 4Health News:Celebrating Four Seasons Resort Maui’s 25th Anniversary 2Health News:PracticeLink to Host a Career Advancement Workshop and Job Fair in Houston 2
... , , Hospitals, ... , PRINCETON, N.J., Aug. 18 Twelve New ... federal government to test an innovative new incentive method that aims ... , The three-year trial program could serve as a ...
... KONG, Aug. 18 IBM (NYSE: IB M ... Life Insurance Company Limited (NYSE: CI ), has implemented ... continuity in the event of disasters or other incidents that could ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090416/ I BMLOGO ) ...
... 18 EwingCole, a nationally recognized architectural, engineering, interior ... today announced that it will combine its practice with ... with a robust portfolio of healthcare projects. The ... September 1, 2009, will create the Delaware Valley,s largest ...
... , , ... systems for targeted, less-invasive medical treatments, today announced that Massachusetts ... iCT, making it second in the nation and third in ... successfully integrate intra-operative imaging -- from high-field MRI to multi-slice ...
... , ARLINGTON, Va., Aug. 18 "Proposed ... add billions of dollars of un-reimbursed cost to the Medicare ... K.C. McAlpin, executive director of ProEnglish, a national organization that ... the United States. , , The ...
... ELM GROVE, Wis., Aug. 18 Long wait times can ... safety . Many hospitals constantly struggle with moving patients in need of critical ... bed. Compirion Healthcare Soluti o ns is ... Improving Patient Flow - ED to Inpatient , free of charge ...
Cached Medicine News:Health News:Medicare Picks N.J. to Test Innovative Incentive System 2Health News:Medicare Picks N.J. to Test Innovative Incentive System 3Health News:Medicare Picks N.J. to Test Innovative Incentive System 4Health News:CIGNA Provides Peace-of-mind for APAC Customers by Ensuring Business Continuity and Resilience with IBM 2Health News:CIGNA Provides Peace-of-mind for APAC Customers by Ensuring Business Continuity and Resilience with IBM 3Health News:CIGNA Provides Peace-of-mind for APAC Customers by Ensuring Business Continuity and Resilience with IBM 4Health News:EwingCole, RDLA Join Together, Creating Architecture/Engineering Firm With Largest Healthcare Focus in the Delaware Valley 2Health News:EwingCole, RDLA Join Together, Creating Architecture/Engineering Firm With Largest Healthcare Focus in the Delaware Valley 3Health News:Massachusetts General Hospital is Second in Nation to Acquire Both BrainSUITE(R) iMRI and iCT 2Health News:Free Compirion Bed Flow Webinar Helps Improve Patient Flow From ED to Inpatient Units 2Health News:Free Compirion Bed Flow Webinar Helps Improve Patient Flow From ED to Inpatient Units 3
For the quantitative determination of Creatine Kinase in serum....
For the quantitative determination of creatine kinase in serum. Kinetic Reaction measured at 340 nm. Linearity: 1500 IU/L at 37C....
For the quantitative determination of total glucose in serum....
Intended for the quantitative determination of glucose in serum. Reaction: endpoint. Wavelength: 500 nm. Linearity: 500 mg/dL (27.8 mmol/L)....
Medicine Products: